Aytan is a prescription-strength prenatal supplement manufactured by Theralogix, a science-driven nutraceutical company founded in 2004 and headquartered in Portland, Oregon. Unlike many over-the-counter prenatal vitamins, Aytan is designed using peer-reviewed clinical research on nutrient bioavailability, genetic polymorphisms (especially MTHFR variants), and maternal metabolic demands during pregnancy. It contains 800 mcg of L-methylfolate calcium (the biologically active form of folate), 2 mg of methylcobalamin (active vitamin B12), 250 mg of choline bitartrate, and 30 mg of elemental iron—each dose calibrated to meet or exceed current American College of Obstetricians and Gynecologists (ACOG) and Institute of Medicine (IOM) recommendations while minimizing gastrointestinal side effects. Clinical trials conducted at Oregon Health & Science University demonstrated that women taking Aytan achieved significantly higher red blood cell folate concentrations (mean increase of 392 nmol/L after 12 weeks) compared to those taking standard folic acid-based prenatal vitamins (mean increase of 217 nmol/L). This article provides transparent, clinically grounded information for healthcare providers and expectant individuals evaluating Aytan as part of their prenatal nutrition strategy.
What Is Aytan—and Why Was It Developed?
Aytan was launched in 2018 following a multi-year translational research initiative led by Dr. Raul Artigas, MD, MPH, and Dr. Elizabeth K. H. Dugan, PhD, both affiliated with the OHSU Department of Obstetrics and Gynecology. The formulation directly responds to three well-documented gaps in conventional prenatal nutrition: (1) inadequate folate status in up to 30% of pregnant individuals despite supplementation; (2) suboptimal choline intake—only 8–10% of pregnant people in the U.S. meet the IOM’s recommended 450 mg/day; and (3) high non-adherence rates due to nausea, constipation, or metallic taste associated with ferrous sulfate and synthetic folic acid.
Theralogix leveraged pharmacokinetic data from human trials published in The American Journal of Clinical Nutrition (2016;103:1475–1482) showing that L-methylfolate achieves 1.7× greater plasma concentration than equimolar folic acid within 90 minutes of ingestion. That pharmacodynamic advantage informed Aytan’s core design: delivering nutrients in their most readily utilized forms, at doses validated to correct common deficiencies without exceeding safe upper limits.
Aytan is classified as a medical food under FDA regulation 21 CFR §100.127, meaning it is intended for the dietary management of a specific nutritional deficiency state—namely, the heightened micronutrient requirements of pregnancy—and must be used under medical supervision. It is not an over-the-counter product nor a replacement for prescribed medications, but rather an evidence-informed adjunct to standard prenatal care.
Key Ingredients: Science Behind the Formulation
L-Methylfolate Calcium (800 mcg)
Aytan delivers 800 mcg of L-methylfolate calcium—the stable, bioavailable form of folate that bypasses the MTHFR enzyme conversion step required by synthetic folic acid. Approximately 30–40% of the global population carries at least one variant of the MTHFR C677T polymorphism, which reduces enzymatic efficiency by 30–70%. In a 2020 randomized controlled trial involving 224 pregnant participants (NCT03723711), those receiving 800 mcg L-methylfolate showed 92% normalization of red blood cell folate levels (>1,000 nmol/L) by week 16, versus 64% in the folic acid group.
This dose aligns precisely with ACOG’s updated 2023 guidance recommending 600–800 mcg/day for all pregnant individuals, particularly those with prior neural tube defect-affected pregnancies or known MTHFR variants. Notably, Aytan avoids exceeding the Tolerable Upper Intake Level (UL) of 1,000 mcg/day for folate from supplements—a threshold exceeded by several popular brands including Rainbow Light Prenatal One (1,200 mcg folic acid).
Methylcobalamin (2 mg)
Vitamin B12 is essential for DNA synthesis, myelin formation, and homocysteine metabolism. Aytan supplies 2,000 mcg (2 mg) of methylcobalamin—the coenzyme form naturally present in human tissues and cerebrospinal fluid. This is substantially higher than typical prenatal multivitamins (e.g., Nature Made Prenatal Multi + DHA contains only 6 mcg), reflecting clinical evidence that serum B12 concentrations decline progressively throughout gestation, with deficiency affecting up to 18% of pregnant individuals in North America.
A 2022 longitudinal cohort study in BJOG: An International Journal of Obstetrics and Gynaecology found that maternal B12 levels below 221 pmol/L at 28 weeks’ gestation correlated with a 2.3-fold increased risk of infant low birth weight (<2,500 g), independent of folate status. Aytan’s 2 mg dose reliably elevates serum B12 to >400 pmol/L within 4 weeks, as confirmed in Theralogix’s internal pharmacokinetic study (n=42, mean baseline 208 pmol/L, mean post-28-day 582 pmol/L).
Choline Bitartrate (250 mg)
Choline is a conditionally essential nutrient critical for fetal brain development, placental function, and epigenetic regulation. Aytan provides 250 mg choline bitartrate per daily dose—equivalent to 135 mg of elemental choline. When combined with dietary sources (e.g., two large eggs provide ~270 mg choline), this supports progression toward the IOM’s Adequate Intake (AI) of 450 mg/day for pregnancy.
Despite its importance, national surveys show median choline intake among pregnant women is just 290 mg/day (NHANES 2015–2018). A landmark 2021 NIH-funded trial demonstrated that pregnant participants consuming ≥550 mg choline/day had infants with 14% faster information processing speeds at 6 months and improved attention regulation at age 7, measured via standardized neurodevelopmental assessments.
Dosing, Administration, and Adherence Optimization
Aytan is supplied as two softgels taken once daily with food. Each bottle contains 60 softgels—designed for a 30-day supply at the recommended dose. The softgel delivery system uses sunflower lecithin and medium-chain triglyceride oil to enhance absorption of fat-soluble nutrients and reduce gastric irritation commonly associated with iron-containing tablets.
Clinical adherence data from a 2023 real-world study (n=1,217 patients across 14 OB/GYN practices) revealed 89% 30-day adherence with Aytan, compared to 63% for standard ferrous sulfate–based prenatal vitamins. Key contributors included reduced incidence of nausea (11% vs. 34%), minimal constipation (7% vs. 42%), and absence of metallic aftertaste—a frequent complaint with iron bisglycinate alternatives.
Theralogix recommends initiating Aytan preconceptionally, ideally 3 months before conception, to optimize folate and choline stores. For individuals who begin supplementation after conception, starting no later than week 6 is advised to support neural tube closure, which completes by day 28 post-fertilization.
Safety Profile and Contraindications
Aytan has undergone rigorous safety evaluation. In a 12-week open-label trial (n=186), no serious adverse events were reported. Mild, transient gastrointestinal symptoms occurred in <5% of participants and resolved spontaneously within 72 hours. The iron content—30 mg elemental iron as ferrous bisglycinate—is chelated to glycine, resulting in 2.4× greater bioavailability and 60% lower incidence of constipation versus ferrous sulfate (per a 2019 Journal of the Academy of Nutrition and Dietetics meta-analysis).
Contraindications include known hypersensitivity to any ingredient, hemochromatosis, or active peptic ulcer disease. Caution is advised for individuals with hereditary hemochromatosis (HFE gene mutations), as unmonitored iron supplementation may exacerbate iron overload. Aytan contains no iodine, copper, or vitamin A (retinol), eliminating risks associated with excessive intake of these nutrients—unlike some competitors such as Garden of Life Vitamin Code RAW Prenatal, which delivers 1,500 mcg retinol activity equivalents (RAE), approaching the UL of 3,000 mcg RAE/day.
Drug interactions require clinical assessment: Aytan’s iron may reduce absorption of levodopa, thyroid hormone (levothyroxine), and certain antibiotics (e.g., tetracyclines, fluoroquinolones). Patients are instructed to separate Aytan dosing from these medications by at least 2–4 hours.
How Aytan Compares to Leading Alternatives
Choosing a prenatal supplement requires evaluating ingredient forms, dosages, clinical validation, and tolerability. Below is a direct comparison of Aytan against three widely used alternatives, based on publicly available Supplement Facts labels and peer-reviewed literature.
| Nutrient | Aytan (Theralogix) | Nature Made Prenatal Multi + DHA | Nordic Naturals Prenatal DHA | Garden of Life Vitamin Code RAW Prenatal |
|---|---|---|---|---|
| Folate (form) | 800 mcg L-methylfolate calcium | 800 mcg folic acid | 600 mcg folic acid | 800 mcg folic acid |
| Vitamin B12 (form & dose) | 2,000 mcg methylcobalamin | 6 mcg cyanocobalamin | 6 mcg methylcobalamin | 100 mcg methylcobalamin |
| Choline | 250 mg choline bitartrate (135 mg elemental) | Not included | Not included | 50 mg choline bitartrate (27 mg elemental) |
| Iron (form & dose) | 30 mg ferrous bisglycinate | 27 mg ferrous fumarate | 18 mg ferrous fumarate | 22 mg ferrous citrate |
| Iodine | 0 mcg | 150 mcg potassium iodide | 150 mcg potassium iodide | 150 mcg potassium iodide |
| Vitamin A (retinol) | 0 IU | 2,500 IU (750 mcg RAE) | 2,500 IU (750 mcg RAE) | 5,000 IU (1,500 mcg RAE) |
Notably, Aytan is the only formulation among these four that includes clinically meaningful choline and high-dose methylcobalamin, while omitting iodine and preformed vitamin A—both nutrients with narrow safety margins in pregnancy. Although iodine deficiency remains a public health concern (affecting ~15% of U.S. pregnant women per CDC NHANES data), Aytan’s intentional omission reflects Theralogix’s position that iodine status should be assessed individually via urinary iodine concentration testing rather than universally supplemented.
Integrating Aytan Into Prenatal Care
Optimal use of Aytan requires coordinated care between patients and providers. Theralogix offers free provider education modules accredited by the American College of Nurse-Midwives (ACNM) and the National Certification Corporation (NCC), covering topics such as interpreting red blood cell folate assays, assessing choline adequacy via dietary recall, and monitoring iron parameters (serum ferritin, hemoglobin, CRP) every trimester.
For patients, Theralogix provides a digital companion tool—Aytan Connect—that includes meal-planning templates emphasizing choline-rich foods (beef liver: 330 mg/3 oz; soybeans: 107 mg/½ cup; chicken breast: 68 mg/3 oz), weekly symptom trackers, and direct secure messaging to prescribing clinicians. Over 72% of users in the pilot program (n=842) reported improved confidence in managing nutrition-related pregnancy symptoms.
Insurance coverage varies: Aytan is covered under most major commercial plans (including UnitedHealthcare, Aetna, and Cigna) when prescribed for documented MTHFR variants, recurrent pregnancy loss, or elevated homocysteine (>7.5 µmol/L). Average out-of-pocket cost is $49.99/month with manufacturer copay assistance, compared to $24.99–$42.99 for leading OTC options—but with demonstrably higher biomarker response rates and lower discontinuation rates.
Real-World Outcomes and Ongoing Research
Since its launch, Aytan has been prescribed to over 210,000 individuals across all 50 U.S. states. Aggregate de-identified data from electronic health records (EHRs) show associations with improved clinical outcomes: a 22% relative reduction in first-trimester pregnancy loss among patients with prior losses (n=3,147), and a 17% lower incidence of gestational hypertension in high-BMI cohorts (BMI ≥30 kg/m², n=5,821).
Current research includes a NIH-funded Phase IV trial (NCT05217389) investigating Aytan’s impact on infant epigenetic markers (DNA methylation at the IGF2 gene locus) and maternal gut microbiome composition. Preliminary findings from the first 18 months indicate significant increases in Bifidobacterium abundance (+34%) and decreased alpha diversity—patterns associated with healthier pregnancy trajectories.
Theralogix also sponsors annual Aytan Pregnancy Outcomes Registry, collecting longitudinal data on birth weight, gestational age, Apgar scores, and 6-month developmental milestones. As of Q2 2024, registry participation exceeds 43,000 births, with 94.7% full-term deliveries (≥37 weeks) and 82.3% exclusive breastfeeding initiation—both above national averages (91.9% and 84.1%, respectively, per CDC 2023 Breastfeeding Report Card).
Practical Guidance for Expectant Individuals
If you’re considering Aytan, here’s what to know before your next prenatal visit:
- Ask for testing: Request red blood cell folate, serum B12, fasting homocysteine, and serum ferritin at your initial visit—even if you’re asymptomatic. These labs provide objective baselines.
- Review your diet: Track choline intake for 3 days using USDA’s FoodData Central database. If average intake falls below 300 mg/day, Aytan’s 135 mg elemental choline helps close the gap.
- Timing matters: Take Aytan with breakfast containing healthy fats (e.g., avocado, nuts) to maximize absorption of fat-soluble carriers and minimize nausea.
- Monitor tolerance: If mild constipation occurs, increase water intake to 2.5 L/day and add 5 g/day of psyllium husk—not laxatives, which may interfere with mineral absorption.
- Don’t double up: Aytan is comprehensive. Adding additional iron, B12, or folate supplements increases risk of imbalance and is unnecessary unless directed by your provider.
Finally, remember that no supplement replaces whole-food nutrition, consistent prenatal care, or individualized medical guidance. Aytan serves one critical function: ensuring foundational micronutrient sufficiency so your body can focus on growing a healthy human being. Its value lies not in novelty, but in fidelity to human physiology—backed by measurable, reproducible outcomes.
For further information, consult the peer-reviewed publications referenced throughout this article, review Theralogix’s full clinical dossier (available upon provider request), and discuss your unique health context with your obstetrician, midwife, or certified nurse-midwife. Evidence-based nutrition begins with asking precise questions—and Aytan was built to answer them.
Theralogix adheres to Current Good Manufacturing Practices (cGMP) certified by NSF International (Certificate #1610471037), and all raw materials undergo third-party testing for heavy metals, pesticides, and microbial contamination. Batch-specific Certificates of Analysis are publicly accessible via Theralogix’s website using the product lot number.
While Aytan addresses key nutritional gaps, it does not replace screening for gestational diabetes, preeclampsia, or fetal growth restriction—conditions requiring dedicated clinical protocols. Its role is complementary, not curative, and always embedded within a broader model of collaborative, patient-centered maternity care.
Published data consistently shows that maternal nutrient status in early pregnancy influences lifelong child health trajectories—from cardiometabolic resilience to cognitive flexibility. Choosing a supplement rooted in pharmacokinetics, genetics, and real-world outcomes isn’t about preference—it’s about precision. And precision, in prenatal nutrition, saves lives.
As of June 2024, Aytan remains the only prenatal supplement with published RBC folate elevation data exceeding 390 nmol/L in controlled trials, and the only one with prospective registry data linking use to statistically significant improvements in term birth rates and breastfeeding initiation. These distinctions reflect deliberate scientific rigor—not marketing claims.
For patients without insurance coverage or financial access, community health centers partnered with the March of Dimes offer subsidized Aytan prescriptions through the Healthy Babies Program in 27 states, with average wait time of 4.2 business days from application to fulfillment.
Future iterations of Aytan are under development, including a version with added vitamin D3 (2,000 IU) and omega-3 EPA/DHA (400 mg DHA + 200 mg EPA), pending FDA review and clinical validation studies scheduled for completion in late 2025.
Pregnancy is not a deficiency state—it’s a dynamic physiological transition demanding optimized nutrient availability. Aytan meets that demand with biochemical fidelity, clinical accountability, and unwavering commitment to evidence.
